Division of Colorectal Surgery, Department of Surgery, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY.
Institute of Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI.
Surgery. 2021 Apr;169(4):759-766. doi: 10.1016/j.surg.2020.11.006. Epub 2020 Dec 4.
Surgery is a common gateway to opioid-related morbidity. Ambulatory anorectal cases are common, with opioids widely prescribed, but there is limited data on their role in this crisis. We sought to determine prescribing trends, new persistent opioid use rates, and factors associated with new persistent opioid use after ambulatory anorectal procedures.
The Optum Clinformatics claims database was analyzed for opioid-naïve adults undergoing outpatient hemorrhoid, fissure, or fistula procedures from January 1, 2010, to June 30, 2017. The main outcome measure was the rate of new persistent opioid use after anorectal cases. Secondary outcomes were annual rates of perioperative opioid fills and the prescription size over time (oral morphine equivalents).
A total of 23,426 cases were evaluated: 69.09% (n = 16,185) hemorrhoids, 24.29% (n = 5,690) fissures, and 6.45% (n = 1,512) fistulas. The annual rate of perioperative opioid fills decreased on average 1.2%/year, from 72% in 2010 to 66% in 2017 (P < .001). Prescribing rates were consistently highest for fistulas, followed by hemorrhoids, then fissures (P < .001). There was a significant reduction in prescription size (oral morphine equivalents) over the study period, with median oral morphine equivalents (interquartile range) of 280 (250-400) in 2010 and 225 (150-375) in 2017 (P < .0001). Overall, 2.1% (n = 499) developed new persistent opioid use. Logistic regression found new persistent opioid use was associated with additional perioperative opioid fills (odds ratio 3.92; 95% confidence interval: 2.92-5.27; P < .0001), increased comorbidity (odds ratio 1.15; confidence interval: 1.09-1.20; P < .00001), tobacco use (odds ratio 1.79; confidence interval: 1.37-2.36; P < .0001), and pain disorders (odds ratio, 1.49; confidence interval, 1.23-1.82); there was no significant association with procedure performed.
Over 2% of ambulatory anorectal procedures develop new persistent opioid use. Despite small annual reductions in opioid prescriptions, there has been little change in the amount prescribed. This demonstrates a need to develop and disseminate best practices for anorectal surgery, focusing on eliminating unnecessary opioid prescribing.
手术是阿片类药物相关发病率的常见途径。肛门直肠门诊病例很常见,常开具阿片类药物,但有关这些病例在这场危机中的作用的数据有限。我们试图确定阿片类药物门诊肛门直肠手术后开具阿片类药物的趋势、新持续性阿片类药物使用的发生率以及与新持续性阿片类药物使用相关的因素。
分析 2010 年 1 月 1 日至 2017 年 6 月 30 日期间,接受门诊痔、肛裂或瘘手术的阿片类药物初治成年人的 Optum Clinformatics 索赔数据库。主要结局指标为肛门直肠手术后新发持续性阿片类药物使用的发生率。次要结局指标为围手术期阿片类药物用量的年度变化和随时间推移的处方剂量(口服吗啡等效剂量)。
共评估了 23426 例病例:69.09%(n=16185)为痔,24.29%(n=5690)为肛裂,6.45%(n=1512)为瘘。围手术期阿片类药物用量的年度减少率平均为 1.2%/年,从 2010 年的 72%降至 2017 年的 66%(P<0.001)。开处方率始终最高的是瘘,其次是痔,然后是肛裂(P<0.001)。研究期间,处方剂量(口服吗啡等效剂量)显著减少,中位数口服吗啡等效剂量(四分位间距)从 2010 年的 280(250-400)降至 2017 年的 225(150-375)(P<0.0001)。总体而言,有 2.1%(n=499)的患者出现新发持续性阿片类药物使用。逻辑回归发现,新发持续性阿片类药物使用与围手术期阿片类药物用量增加(比值比 3.92;95%置信区间:2.92-5.27;P<0.0001)、合并症增多(比值比 1.15;置信区间:1.09-1.20;P<0.00001)、吸烟(比值比 1.79;置信区间:1.37-2.36;P<0.0001)和疼痛障碍(比值比 1.49;置信区间:1.23-1.82)有关,与所施行的手术无显著相关性。
超过 2%的门诊肛门直肠手术出现新发持续性阿片类药物使用。尽管阿片类药物处方的年减少量较小,但开具的药物数量几乎没有变化。这表明需要制定和传播肛门直肠手术的最佳实践,重点是消除不必要的阿片类药物处方。